Healthcare Industry News: sanofi-aventis
News Release - December 17, 2009
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & QualityWALTHAM, Mass.--(HSMN NewsFeed)--ImmunoGen, Inc. (Nasdaq: IMGN ), a biotechnology company that develops targeted anticancer products, announced today the appointment of Suzanne Cadden as Vice President of Regulatory Affairs & Quality. Ms. Cadden will be responsible for establishing – in conjunction with the Chief Medical Officer – the registration strategy for the Company’s product candidates, for directing the development of regulatory submissions prepared by ImmunoGen in support of its own programs and those of its partners, and for managing the Company’s manufacturing-associated quality functions. Ms. Cadden reports to Daniel Junius, ImmunoGen President and Chief Executive Officer.
“Suzanne brings to ImmunoGen extensive regulatory experience – both with the FDA and with international agencies – that we expect will be highly beneficial to our advancement of our own product candidates and our support of partner programs,” commented Daniel Junius. “Further, I believe that as a member of our senior management team, Suzanne will play an important role in our taking ImmunoGen to the next level.”
Ms. Cadden brings to ImmunoGen over 20 years of experience gained at both pharmaceutical and biotechnology companies. Prior to joining ImmunoGen, she was Vice President of Regulatory Affairs & Clinical Development at Sierra Neuropharmaceuticals Inc., where she was responsible for developing global regulatory and clinical strategies for novel therapeutics with a focus on the US and Europe. Before that, she was Vice President of Regulatory Affairs & Clinical Operations at ActivBiotics Inc. in Boston, MA, where she oversaw the development of global regulatory/clinical strategies, including Phase II and III clinical programs. Before joining ActivBiotics Inc., Ms. Cadden held senior positions at Transition Therapeutics, LORUS Therapeutics, Glaxo Wellcome, Inc. and CIBA, Canada. Ms. Cadden has published in her areas of expertise and holds a M.Sc. in Pharmacology from the University of Western Ontario and a B.Sc. in Biochemistry & Nutrition from the University of Guelph.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.